Bristol-Myers-Squibb Anticipates FDA Approval for CC-486 as a Treatment for Acute Myeloid Leukemia
After registering positive results in Phase 3, QUAZAR AML-001 trial, the company would be expecting the oral hypomethylating agent to notch FDA authorization this week. By Pavel Ryzhov, Ph.D. In …
Read More